What's in the Cards for CME Group This Earnings Season?

CME Group is projected to report a decline in its Q3 2025 top and bottom lines, with Zacks Consensus Estimates forecasting revenues of $1.54 billion (down 2.9% year-over-year) and earnings of $2.63 per share (down 1.8% year-over-year), following a recent 3.3% downward revision to the EPS estimate. While the company is expected to benefit from a diverse product portfolio, increased volatility, and growth in market data services (up 10.1% YoY) and agricultural/metals average daily volumes (up 6% and 13% respectively), these gains are offset by a 10% year-over-year decrease in overall average daily volume, driven by lower activity in interest rates, equities, energy, and FX products, alongside an anticipated 3.4% rise in expenses. The company currently holds a Zacks Rank of 4 (Sell) with an Earnings ESP of 0.00%.

Analysis

CME Group is projected to report a decline in its third-quarter 2025 financial results, with Zacks Consensus Estimates forecasting revenues of $1.54 billion, a 2.9% year-over-year decrease, and earnings per share of $2.63, representing a 1.8% year-over-year decline. The EPS estimate has seen a 3.3% downward revision over the past 30 days, signaling cautious analyst sentiment ahead of the October 22 report.

Operational performance shows mixed signals; while overall average daily volume (ADV) decreased 10% year-over-year to 25.3 million contracts, driven by lower activity in Interest Rates, Equities, Energy, and FX products, specific segments demonstrated growth. Agricultural ADV rose 6% year-over-year, and Metals ADV increased 13% year-over-year. Market data and information services revenues are also expected to climb 10.1% year-over-year to $196 million.

Despite these positive segment trends, anticipated expenses are set to increase 3.4% year-over-year to $505.6 million, primarily due to higher compensation, benefits, and technology costs. The company currently holds a Zacks Rank of 4 (Sell), suggesting potential underperformance, despite a model prediction of an earnings beat which is contradicted by the current rank.

Key Decisions for Investors

• Investors should closely monitor CME Group's Q3 2025 earnings report for confirmation of the projected revenue and EPS declines, as well as any forward guidance.
• Evaluate the detailed breakdown of average daily volumes to understand if the growth in Agricultural and Metals segments can offset broader declines in other key product areas.
• Given the Zacks Rank of 4 (Sell) and anticipated expense increases, consider potential downside risks or the need for a more cautious stance on CME shares.